CD27 and rheumatoid arthritis: Recently, a study of peripheral blood and tonsilar biopsies from RA patients undergoing treatment with the combined TNF and lymphotoxin α (LTα) antagonist, etanercept, suggested that part of the success of this therapy in RA could be linked to a disruption of follicular dendritic cell (FDC) networks in secondary lymphoid organs, thus impairing germinal centre formation, and decreasing the number of CD27+memory B cells in the blood [19].